Bernhard Mraz
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Tracking economic change over a decade: an analysis of Austria's industry-sponsored clinical trial landscape and implications for policy.
Journal: Journal of medical economics
Published: June 08, 2026
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Journal: Melanoma research
Published: December 13, 2023
A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making.
Journal: Scientific reports
Published: October 09, 2023
Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus.
Journal: JMIR medical informatics
Published: October 11, 2021
Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.
Journal: Journal of medical economics
Published: February 13, 2020
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Journal: Breast (Edinburgh, Scotland)
Published: July 12, 2019
Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study.
Journal: Clinical genitourinary cancer
Published: March 19, 2019
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 17, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026